Mesa Laboratories, Inc. (NASDAQ:MLAB) Director H Stuart Campbell sold 1,000 shares of Mesa Laboratories stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $137.61, for a total transaction of $137,610.00. Following the transaction, the director now directly owns 46,976 shares of the company’s stock, valued at $6,464,367.36. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

H Stuart Campbell also recently made the following trade(s):

  • On Thursday, August 10th, H Stuart Campbell sold 1,000 shares of Mesa Laboratories stock. The shares were sold at an average price of $136.58, for a total transaction of $136,580.00.
  • On Friday, August 4th, H Stuart Campbell sold 1,000 shares of Mesa Laboratories stock. The shares were sold at an average price of $143.09, for a total transaction of $143,090.00.
  • On Thursday, August 3rd, H Stuart Campbell sold 2,000 shares of Mesa Laboratories stock. The shares were sold at an average price of $143.37, for a total transaction of $286,740.00.

Mesa Laboratories, Inc. (MLAB) traded down 0.532% during trading on Friday, hitting $135.495. 12,137 shares of the stock traded hands. The firm’s 50-day moving average is $144.21 and its 200-day moving average is $135.91. Mesa Laboratories, Inc. has a 12 month low of $102.14 and a 12 month high of $169.81. The stock has a market cap of $509.19 million, a P/E ratio of 48.704 and a beta of 0.46.

Mesa Laboratories (NASDAQ:MLAB) last issued its quarterly earnings results on Monday, July 31st. The medical instruments supplier reported $0.39 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.56 by $0.17. Mesa Laboratories had a return on equity of 16.58% and a net margin of 11.31%. The company had revenue of $22.67 million for the quarter, compared to analyst estimates of $22.90 million. On average, analysts forecast that Mesa Laboratories, Inc. will post $2.72 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Thursday, August 31st will be issued a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.47%. The ex-dividend date is Tuesday, August 29th. Mesa Laboratories’s dividend payout ratio is presently 22.94%.

WARNING: This piece was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.watchlistnews.com/mesa-laboratories-inc-nasdaqmlab-director-sells-137610-00-in-stock/1472758.html.

Several large investors have recently modified their holdings of the company. Royce & Associates LP increased its stake in shares of Mesa Laboratories by 56.8% in the second quarter. Royce & Associates LP now owns 78,530 shares of the medical instruments supplier’s stock valued at $11,254,000 after buying an additional 28,458 shares in the last quarter. Thomson Horstmann & Bryant Inc. increased its stake in shares of Mesa Laboratories by 75.4% in the second quarter. Thomson Horstmann & Bryant Inc. now owns 72,362 shares of the medical instruments supplier’s stock valued at $10,370,000 after buying an additional 31,107 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC increased its stake in Mesa Laboratories by 4.5% in the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 70,189 shares of the medical instruments supplier’s stock worth $10,059,000 after buying an additional 3,001 shares during the period. Pembroke Management LTD acquired a new stake in Mesa Laboratories during the second quarter worth approximately $8,283,000. Finally, King Luther Capital Management Corp increased its stake in Mesa Laboratories by 24.4% in the second quarter. King Luther Capital Management Corp now owns 30,491 shares of the medical instruments supplier’s stock worth $4,370,000 after buying an additional 5,980 shares during the period. 66.72% of the stock is owned by hedge funds and other institutional investors.

Several research firms have recently weighed in on MLAB. TheStreet lowered shares of Mesa Laboratories from a “b” rating to a “c+” rating in a report on Monday, July 31st. Zacks Investment Research raised shares of Mesa Laboratories from a “hold” rating to a “buy” rating and set a $159.00 target price for the company in a report on Tuesday, June 13th. Finally, BidaskClub lowered shares of Mesa Laboratories from a “hold” rating to a “sell” rating in a report on Monday, July 31st.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.

Insider Buying and Selling by Quarter for Mesa Laboratories (NASDAQ:MLAB)

Receive News & Ratings for Mesa Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.